Abstract: A method includes the following operations: identifying a layer of a first layout based on a first violation generated on the layer; generating a metal density value associated with the layer; when the metal density value is larger than or equal to a preset value, classifying the first violation into a first class corresponding to routing congestions of the first layout; when the first violation is classified into the first class, assigning, to the first violation, a first operation of a plurality of first pre-stored operations corresponding to the first class; and performing the first operation to the first layout to generate a second layout.

Abstract: A method for modifying glycoproteins is provided. The present disclosure also provides a method for producing glycoprotein-payload conjugates, the conjugates produced thereby, and the use thereof.

Abstract: The present disclosure provides an immunoconjugate includes an antibody comprising an antigen-binding fragment that specifically binds to an epitope in mesothelin, N-glycan binding domain and an N-glycan; a linker linking to the N-glycan; and a payload A and a payload B conjugated to the linker, respectively; wherein the payload A and the payload B are the same or different. A pharmaceutical composition comprises the immunoconjugate and a method for treating cancer are also provided in the disclosure.

Abstract: A filtering module includes at least one reinforced aluminum side plate and at least one filtering mesh. The reinforced aluminum side plate surrounds to form a rectangular frame. The reinforced aluminum side plate includes a top plate, a connecting plate, a base plate and a positioning plate. The connecting plate is connected between the top plate and the base plate. The base plate and the top plate are substantially parallel with each other. The base plate has a treated surface away from the top plate and configured to abut against a fan filtering unit. The top plate has a supporting surface away from the base plate. The positioning plate is disposed perpendicularly on the supporting plate and aligns with the connecting plate. The filtering mesh is at least partially supported on the supporting surface and at least partially abuts against the positioning plate.

Abstract: An immunoconjugate, comprising an anti-EGFR antibody or a binding fragment thereof, and a kinase inhibitor.

Abstract: The present disclosure provides an immunoconjugate includes an antibody comprising an antigen-binding fragment that specifically binds to an epitope in mesothelin, N-glycan binding domain and an N-glycan; a linker linking to the N-glycan; and a payload A and a payload B conjugated to the linker, respectively; wherein the payload A and the payload B are the same or different. A pharmaceutical composition comprises the immunoconjugate and a method for treating cancer are also provided in the disclosure.

Abstract: A filtering module includes at least one reinforced aluminum side plate and at least one filtering mesh. The reinforced aluminum side plate surrounds to form a rectangular frame. The reinforced aluminum side plate includes a top plate, a connecting plate, a base plate and a positioning plate. The connecting plate is connected between the top plate and the base plate. The base plate and the top plate are substantially parallel with each other. The base plate has a treated surface away from the top plate and configured to abut against a fan filtering unit. The top plate has a supporting surface away from the base plate. The positioning plate is disposed perpendicularly on the supporting plate and aligns with the connecting plate. The filtering mesh is at least partially supported on the supporting surface and at least partially abuts against the positioning plate.

Abstract: A process for modifying glycoproteins is provided. The invention also provides a process for producing glycoprotein-payload conjugates, as well as the conjugates produced thereby.

Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.

Abstract: An immunoconjugate includes an anti-Globo H antibody, or a binding fragment thereof, and a therapeutic agent or a label, having the formula: Ab?(L?D)m, wherein Ab is the anti-Globo H antibody or the binding fragment thereof, L is a linker or a direct bond, D is the therapeutic agent or the label, and m is an integer from 1 to 8. The antibody may be a monoclonal antibody, which may be a humanized antibody. A method for treating a cancer includes administering to a subject in need of such treatment a pharmaceutically effective amount of an immunoconjugate containing an antibody against Globo H, or a binding fragment thereof, and a therapeutic agent covalently conjugated with the antibody.

Abstract: An immunoconjugate having the Formula Ab-[L1-(A-L2-B)m]n, wherein: (a) Ab is an antibody or a binding fragment thereof; (b) L1 and L2 are each independently a linker, wherein L1 and L2 are the same or different and wherein L1 links to L2; (c) A is a target-protein ligand/binder; (d) B is a ubiquitin ligase ligand/binder, and (e) n and m are independently integers from 1 to 8. The target protein includes kinase, G protein-coupled receptors, transcription factor, phosphatases, and RAS superfamily members.

Abstract: Disclosed herein are methods for high-throughput screening of a functional antibody fragment for an immunoconjugate that targets a protein antigen. The method combines a phage-displayed synthetic antibody library and high-throughput cytotoxicity screening of non-covalently assembled immunotoxins or cytotoxic drug to identify highly functional synthetic antibody fragments for delivering toxin payloads.

Abstract: An immunoconjugate, comprising an anti-EGFR antibody or a binding fragment thereof, and a kinase inhibitor.